No profile data available.
Invivyd, Inc. (IVVD) is a healthcare company in the antiviral pharmaceuticals industry, based in New Haven, United States, with about 122 full-time employees.
It reported revenue of $53.43 million for fiscal year 2025, up 110.5% from fiscal year 2024, and net income of -$52.49 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $14.29 million, up 21.2% from a year before. Its market capitalization was $212.58 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States.
Invivyd reported $53.43 million in revenue for fiscal year 2025, up 110.5% from $25.38 million in fiscal year 2024. In Q2 2026 revenue was $14.29 million.
$212.58 million as of October 9, 2026.
Listed companies of a similar size in the same industry (antiviral pharmaceuticals) include SAB Biotherapeutics, Inc. (SABS), InflaRx N.v. (IFRX), Siga Technologies, Inc. (SIGA), Vaxart, Inc. (VXRT).